High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer

Neoplasia

Volumn 7, Issue 6, 2005, Pages 603-613

  Bernardini, Marcus ^a,b   Lee, Chung Hae ^a   Beheshti, Ben ^a   Prasad, Mona ^c   Albert, Monique ^c   Marrano, Paula ^a   Begley, Heather ^c   Shaw, Patricia ^b,c,e   Covens, Al ^d   Murphy, Joan ^e   Rosen, Barry ^e   Minkin, Salomon ^a,b   Squire, Jeremy A ^a,b   Macgregor, Pascale F ^c,f  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f Canadian Breast Cancer Foundation Ontario Chapter   (Canada)

Author keywords

Cisplatin; Gene amplification; Gene deletion; Microarray data mining; Taxol

Indexed keywords

ARTICLE; CANCER CHEMOTHERAPY; CHROMOSOME 11P; CHROMOSOME 13Q; CHROMOSOME 15Q; CHROMOSOME 17Q; CHROMOSOME 18Q; CHROMOSOME 1P; CHROMOSOME 1Q; CHROMOSOME 21Q; CHROMOSOME 6P; CHROMOSOME 7Q; CHROMOSOME 9Q; COMPARATIVE GENOMIC HYBRIDIZATION; DNA CONFORMATION; DNA DAMAGE; DNA MICROARRAY; GAPD GENE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE LOSS; GENE MAPPING; GENOME; GENOMIC INSTABILITY; GRP58 GENE; HMGB1 GENE; HMGB2 GENE; HSC70 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL;

EID: 22044440210     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.04760     Document Type: Article

References (49)

1. McGuire WP III and Markman M (2003). Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer 89 (Suppl 3), S3-S8.
2. Verheijen RH, von Mensdorff-Pouilly S, van Kamp GJ, and Kenemans P (1999). CA 125: fundamental and clinical aspects. Semin Cancer Biol 9, 117-124.
3. Rustin GJ (2003). Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 21, 187-193.
4. Yamamoto K, Kikuchi Y, Kudoh K, Hirata J, Kita T, and Nagata I (2000). Treatment with paclitaxel alone rather than combination with paclitaxel and cisplatin may be selective for cisplatin-resistant ovarian carcinoma. Jpn J Clin Oncol 30, 446-449.
5. Yamamoto K, Kikuchi Y, Kudoh K, and Nagata I (2000). Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. J Cancer Res Clin Oncol 126, 168-172.
6. Maubant S, Cruet-Hennequart S, Poulain L, Carreiras F, Sichel F, Luis J, Staedel C, and Gauduchon P (2002). Altered adhesion properties and alphav integrin expression in a cisplatin-resistant human ovarian carcinoma cell line. Int J Cancer 97, 186-194.
7. Rogers PM, Beale PJ, AI-Moundhri M, Boxall F, Patterson L, Valenti M, Raynaud F, Hobbs S, Johnston S, and Kelland LR (2002). Overexpression of BclXL in a human ovarian carcinoma cell line: paradoxic effects on chemosensitivity in vitro versus in vivo. Int J Cancer 97, 858-863.
8. Kumar A, Soprano DR, and Parekh HK (2001). Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma. Cancer Res 61, 7552-7555.
9. Yasui K, Mihara S, Zhao C, Okamoto H, Saito-Ohara F, Tomida A, Funato T, Yokomizo A, Naito S, Imoto I, et al. (2004). Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res 64, 1403-1410.
10. Taetle R, Aickin M, Yang JM, Panda L, Emerson J, Roe D, Adair L, Thompson F, Liu Y, Wisner L, et al. (1999). Chromosome abnormalities in ovarian adenocarcinoma: I. Nonrandom chromosome abnormalities from 244 cases. Genes Chromosomes Cancer 25, 290-300.
11. Mertens F, Johansson B, Hoglund M, and Mitelman F (1997). Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. Cancer Res 57, 2765-2780.
12. Bayani J, Brenton JD, Macgregor PF, Beheshti B, Albert M, Nallainathan D, Karaskova J, Rosen B, Murphy J, Laframboise S, et al. (2002). Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. Cancer Res 62, 3466-3476.
13. Bernardini M, Weberpals J, and Squire JA (2004). The use of cytogenetics in understanding ovarian cancer. Biomed Pharmacother 58, 17-23.
14. Parente F, Gaudray P, Carle GF, and Turc-Carel C (1997). Experimental assessment of the detection limit of genomic amplification by comparative genomic hybridization CGH. Cytogenet Cell Genet 78, 65-68.
15. Mantripragada KK, Buckley PG, de Stahl TD, and Dumanski JP (2004). Genomic microarrays in the spotlight. Trends Genet 20, 87-94.
16. Beheshti B, Braude I, Marrano P, Thorner P, Zielenska M, and Squire JA (2003). Chromosomal localization of DNA amplifications in neuroblastoma tumors using cDNA microarray comparative genomic hybridization. Neoplasia 5, 53-62.
17. Pollack JR, Perou CM, Alizadeh AA, Eisen MB, Pergamenschikov A, Williams CF, Jeffrey SS, Botstein D, and Brown PO (1999). Genomewide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet 23, 41-46.
18. Squire JA, Pei J, Marrano P, Beheshti B, Bayani J, Lim G, Moldovan L, and Zielenska M (2003). High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays. Genes Chromosomes Cancer 38, 215-225.
19. Squire JA, Bayani J, Luk C, Unwin L, Tokunaga J, MacMillan C, Irish J, Brown D, Gullane P, and Kamel-Reid S (2002). Molecular cytogenetic analysis of head and neck squamous cell carcinoma: by comparative genomic hybridization, spectral karyotyping, and expression array analysis. Head Neck 24, 874-887.
20. Heiskanen M, Kononen J, Barlund M, Torhorst J, Sauter G, Kallioniemi A, and Kallioniemi O (2001). CGH, cDNA and tissue microarray analyses implicate FGFR2 amplification in a small subset of breast tumors. Anal Cell Pathol 22, 229-234.
21. Fritz B, Schubert F, Wrobel G, Schwaenen C, Wessendorf S, Nessling M, Korz C, Rieker RJ, Montgomery K, Kucherlapati R, et al. (2002). Microarray-based copy number and expression profiling in dedifferentiated and pleomorphic liposarcoma. Cancer Res 62, 2993-2998.
22. Clark J, Edwards S, John M, Flohr P, Gordon T, Maillard K, Giddings I, Brown C, Bagherzadeh A, Campbell C, et al. (2002). Identification of amplified and expressed genes in breast cancer by comparative hybridization onto microarrays of randomly selected cDNA clones. Genes Chromosomes Cancer 34, 104-114.
23. Pollack JR, Sorlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PE, Tibshirani R, Botstein D, Borresen-Dale AL, and Brown PO (2002). Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA 99, 12963-12968.
24. Le Page C, Provencher D, Maugard CM, Ouellet V, Mes-Masson AM (2004). Signature of a silent killer: expression profiling in epithelial ovarian cancer. Expert Rev Mol Diagn 4, 157-167.
25. Simon R, Mirlacher M, and Sauter G (2004). Tissue microarrays. Biotechniques 36, 98-105.
26. Westfall PH and Young SS (1993). Resampling-Based Multiple Testing: Examples and Methods for P-Value Adjustment. Wiley-Interscience, New York.
27. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball CA, Causton HC, et al. (2001). Minimum Information About a Microarray Experiment (MIAME)-toward standards for microarray data. Nat Genet 29, 365-371.
28. Eisen MB, Spellman PT, Brown PO, and Botstein D (1998). Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95, 14863-14868.
29. Tusher VG, Tibshirani R, and Chu G (2001). Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98, 5116-5121.
30. Tibshirani R, Hastie T, Narasimhan B, and Chu G (2002). Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 99, 6567-6572.
31. Trogan E, Choudhury RP, Dansky HM, Rong JX, Breslow JL, and Fisher EA (2002). Laser capture microdissection analysis of gene expression in macrophages from atherosclerotic lesions of apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 99, 2234-2239.
32. Krynetski EY, Krynetskaia NF, Bianchi ME, and Evans WE (2003). A nuclear protein complex containing high mobility group proteins B1 and B2, heat shock cognate protein 70, ERp60, and glyceraldehyde-3-phosphate dehydrogenase is involved in the cytotoxic response to DNA modified by incorporation of anlicancer nucleoside analogues. Cancer Res 63, 100-106.
33. Struski S, Doco-Fenzy M, and Cornillet-Lefebvre P (2002). Compilation of published comparative genomic hybridization studies. Cancer Genet Cytogenet 135, 63-90.
34. Kudoh K, Takano M, Koshikawa T, Hirai M, Yoshida S, Mano Y, Yamamoto K, Ishii K, Kita T, Kikuchi Y, et al. ( 1999). Gains of 1q21-q22 and 13q12-q14 are potential indicators for resistance to cisplatin-based chemotherapy in ovarian cancer patients. Clin Cancer Res 5, 2526-2531.
35. Staebler A, Heselmeyer-Haddad K, Bell K, Riopel M, Perlman E, Ried T, and Kurman RJ (2002). Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas. Hum Pathol 33, 47-59.
36. Launonen V, Mannermaa A, Stenback F, Kosma VM, Puistola U, Huusko P, Anttila M, Bloigu R, Saarikoski S, Kauppila A, et al. (2000). Loss of heterozygosity at chromosomes 3, 6, 8,11,16, and 17 in ovarian cancer: correlation to clinicopathological variables. Cancer Genet Cytogenet 122, 49-54.
37. Dent J, Hall GD, Wilkinson N, Perren TJ, Richmond I, Markham AF, Bell SM, and Bell SM (2003). Cytogenetic alterations in ovarian clear cell carcinoma detected by comparative genomic hybridisation. Br J Cancer 88, 1578-1583.
38. Rhei E, Bogomolniy F, Federici MG, Maresco DL, Offit K, Robson ME, Saigo PE, and Boyd J (1998). Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers. Cancer Res 58, 3193-3196.
39. Concin N, Becker K, Slade N, Erster S, Mueller-Holzner E, Ulmer H, Daxenbicnler G, Zeimet A, Zeillinger R, Marth C, et al. (2004). Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res 64, 2449-2460.
40. Iyengar TD, Ng S, Lau CC, Welch WR, Bell DA, Berkowitz RS, and Mok SC (1999). Differential expression of NF1 type I and type II isoforms in sporadic borderline and invasive epithelial ovarian tumors. Oncogens 18, 257-262.
41. Khan J, Simon R, Bittner M, Chen Y, Leighton SB, Pohida T, Smith PD, Jiang Y, Gooden GC, Trent JM, et al. (1998). Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res 58, 5009-5013.
42. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, et al. (1999). Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531-537.
43. Simon R (2003). Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarray data. Br J Cancer 89, 1599-1604.
44. Orr GA, Verdier-Pinard P, McDaid H, and Horwitz SB (2003). Mechanisms of Taxol resistance related to microtubules. Oncogene 22, 7280-7295.
45. Sugimura M, Sagae S, Ishioka S, Nishioka Y, Tsukada K, and Kudo R (2004). Mechanisms of paclitaxel-induced apoptosis in an ovarian cancer cell line and its paclitaxel-resistant clone. Oncology 66, 53-61.
46. Vargas-Roig LM, Gago FE, Tello O, Aznar JC, and Ciocca DR (1998). Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 79, 468-475.
47. He Q, Liang CH, and Lippard SJ (2000). Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc Natl Acad Sci USA 97, 5768-5772.
48. Phillips JL, Hayward SW, Wang Y, Vasselli J, Pavlovich C, Padilla-Nash H, Pezullo JR, Ghadimi BM, Grossfeld GD, Rivera A, et al. (2001). The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis. Cancer Res 61, 8143-8149.
49. Platzer P, Upender MB, Wilson K, Willis J, Lutterbaugh J, Nosrati A, Willson JK, Mack D, Ried T, and Markowitz S (2002). Silence of chromosomal amplifications in colon cancer. Cancer Res 62, 1134-1138.